Contact
searchSearch
HMP Global
Login
Quiz

Using the PREMM5 Model to Detect Mutations Associated With Lynch Syndrome

11/06/2024

Recent News

FDA Approval
FDA Approves Pembrolizumab for Patients With HER2-Positive, PD-L1 Expressing Gastric or Gastroesophageal Junction Adenocarcinoma
03/19/2025
Based on results from the KEYNOTE-811 study, the FDA has approved first-line pembrolizumab plus trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-positive...
Based on results from the KEYNOTE-811 study, the FDA has approved first-line pembrolizumab plus trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-positive...
Based on results from the...
03/19/2025
Oncology
News
HMP Global’s Great Debates in Solid Tumors events deliver best of three popular oncology conferences
03/19/2025
The best of HMP Global’s three Great Debates programs will be featured in one 2025 series, Great Debates in Solid Tumors, delivering a more comprehensive learning experience for oncology clinicians in the gastrointestinal, women’s and lung...
The best of HMP Global’s three Great Debates programs will be featured in one 2025 series, Great Debates in Solid Tumors, delivering a more comprehensive learning experience for oncology clinicians in the gastrointestinal, women’s and lung...
The best of HMP Global’s three...
03/19/2025
Oncology
Conference Coverage
Addition of Pembrolizumab Does Not Significantly Worsen Quality-of-Life Outcomes for Patients With pMMR Advanced or Recurrent Endometrial Cancer
03/18/2025
According to results from the phase 3 NRG GY018 trial, the addition of pembrolizumab to chemotherapy did not significantly worsen patient-reported quality of life outcomes among patients with proficient mismatch repair advanced or recurrent...
According to results from the phase 3 NRG GY018 trial, the addition of pembrolizumab to chemotherapy did not significantly worsen patient-reported quality of life outcomes among patients with proficient mismatch repair advanced or recurrent...
According to results from the...
03/18/2025
Oncology
Conference Coverage
Puxitatug Samrotecan Demonstrated Promise for Patients With B7-H4–Positive Advanced or Recurrent Endometrial Cancer
03/18/2025
According to results from the phase 1/2a BLUESTAR study, puxitatug samrotecan demonstrated promising efficacy and safety among patients with B7-H4–positive advanced or recurrent endometrial cancer.
According to results from the phase 1/2a BLUESTAR study, puxitatug samrotecan demonstrated promising efficacy and safety among patients with B7-H4–positive advanced or recurrent endometrial cancer.
According to results from the...
03/18/2025
Oncology
News
Brentuximab Vedotin Plus Lenalidomide and Rituximab Improves Survival For Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
03/17/2025
For patients with relapsed/refractory diffuse large B-cell lymphoma, brentuximab vedotin plus lenalidomide and rituximab was associated with improved survival rates and tolerability, according to results from a phase 3 study.
For patients with relapsed/refractory diffuse large B-cell lymphoma, brentuximab vedotin plus lenalidomide and rituximab was associated with improved survival rates and tolerability, according to results from a phase 3 study.
For patients with...
03/17/2025
Oncology
News
Denileukin Diftitox-CXDL Demonstrates Efficacy for Relapsed/Refractory Cutaneous T-Cell Lymphoma
03/17/2025
A recent phase 3 trial evaluating the use of denileukin diftitox-CXDL for relapsed/refractory cutaneous T-cell lymphoma demonstrated reduced skin tumor burden and promising tolerability.
A recent phase 3 trial evaluating the use of denileukin diftitox-CXDL for relapsed/refractory cutaneous T-cell lymphoma demonstrated reduced skin tumor burden and promising tolerability.
A recent phase 3 trial...
03/17/2025
Oncology
News
Mutation Clearance After Allogeneic Stem Cell Transplantation as Prognostic Indicator for Patients With Myelofibrosis
03/17/2025
For patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation, mutation driver clearance at 30 days was associated with improved cancer outcomes, according to study results.
For patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation, mutation driver clearance at 30 days was associated with improved cancer outcomes, according to study results.
For patients with myelofibrosis...
03/17/2025
Oncology
News
Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Improve Survival for EGFR-Mutated Non-Small Cell Lung Cancer
03/14/2025
Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.
Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.
Results from the phase 3 ETOP...
03/14/2025
Oncology
News
Neoadjuvant Tyrosine Kinase Inhibitor Therapy to Downstage Patients With Unresectable Differentiated Thyroid Cancers
03/13/2025
Results from a retrospective review demonstrated that administration of neoadjuvant tyrosine kinase inhibitor therapy can effectively downstage patients with unresectable differentiated thyroid cancers, allowing patients to achieve R0...
Results from a retrospective review demonstrated that administration of neoadjuvant tyrosine kinase inhibitor therapy can effectively downstage patients with unresectable differentiated thyroid cancers, allowing patients to achieve R0...
Results from a retrospective...
03/13/2025
Oncology
News
Lenvatinib Plus Pembrolizumab for Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
03/13/2025
According to results from a multi-cohort study, lenvatinib plus pembrolizumab demonstrated efficacy and safety among patients with progressive, radioiodine-refractory differentiated thyroid cancer.
According to results from a multi-cohort study, lenvatinib plus pembrolizumab demonstrated efficacy and safety among patients with progressive, radioiodine-refractory differentiated thyroid cancer.
According to results from a...
03/13/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use